PTPN11 and Hepatic fibrosis: In this study, to identify novel SHP2 inhibitors for liver fibrosis therapy, we developed a cross-validated high-throughput screening (HTS) DiFMUP assay platform, leading to the identification of Linderalactone (LIN) as a novel SHP2 inhibitor from the NP library.